Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia
Abstract Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton’s tyrosine kinase (BTK), was designed as an alternative strategy to treat ibrutinib-resistant disease that develops due to C481 kinase domain mutations. The clinical activity of pirtobrutinib has been demonstrated in CLL, but the me...
| Main Authors: | , , , , , , , , , |
|---|---|
| פורמט: | Article |
| שפה: | English |
| יצא לאור: |
Nature Publishing Group
2022-05-01
|
| סדרה: | Blood Cancer Journal |
| גישה מקוונת: | https://doi.org/10.1038/s41408-022-00675-9 |